Abhijit Pal

Abhijit Pal

Auto-generated profile, based on publicly available information

Abhijit Pal

Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
APAbhijit Pal
Abhijit Pal
ASAllan Ben Smith
Allan Ben Smith
CAChristie Allan
Christie Allan
DKDeme Karikios
Deme Karikios
FBFrances Boyle
Frances Boyle
Barriers and solutions to cancer clinical trial access in Australia—results from a national survey.

1 March 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Open access
JLJulia Lai-Kwon
Julia Lai-Kwon
CTCrescens Tiu
Crescens Tiu
APAbhijit Pal
Abhijit Pal
SKSachin Khurana
Sachin Khurana
AMAnna R. Minchom
Anna R. Minchom
Epidermal Growth Factor Receptor (EGFR) mutations are the most common targetable oncogenic driver mutation in metastatic non-small lung cancer (NSCLC). There have been significant advances in the management of metastatic EGFR-mutant NSCLC from the advent of first and second generation EGFR inhibitors to, more recently, the third-generation inhibitor osimertinib. Osimeritinib is now established as first-line therapy on the basis of improved outcomes compared to first and second generation agents. However, despite excellent initial response rates, responses may not be durable due to the development of acquired resistance. Understanding these mechanisms of resistance is critical to the development of rational drug and drug combinations capable of circumventing them. We discuss the major mechanisms of resistance to first, second and third generation EGFR TKIs. The potential of drug combinations utilising chemotherapy, immunotherapy and anti-angiogenic drugs are explored. We examine strategies to aid drug development, including circulating tumour DNA and novel trial designs.

2 September 2024 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
APAbhijit Pal
Abhijit Pal
RMRayan Saleh Moussa
Rayan Saleh Moussa
ASAllan Ben Smith
Allan Ben Smith
BBBernadette Brady
Bernadette Brady
DKDeme Karikios
Deme Karikios
WCWei Chua
Wei Chua
In this issue of the Journal, Guadamuz et al. ( 1) report on the relationship between social determinants of health (SDOH) and cancer clinical trial participation among Black and Latinx patients in the Flatiron Health database, which includes data on more than 250 000 patients from 2011 to 2023. Unsurprisingly, they reaffirm substantial disparities in clinical trial participation. Black and Latinx patients are 40%-50% less likely to participate in clinical trials than White patients, despite clear US laws, such as the 1993 National Institutes of Health Revitalization Act ( 2) and laws mandating insurance coverage for trials. This study, however, provides quantifiable estimates of the contribution of different mediators to these disparities, which is a notable step forward in the trial participation literature. As shown in previous studies ( 3), it does not appear that patients from minoritized populations decline offers of trial participation—rather, they are not provided with the opportunity to participate because of where they reside or health-care professional biases. Similar to their previous research ( 4), the authors link trial data to American Community Survey and US Census Bureau data and relate area-level SDOH factors to the outcome of interest. This database linkage enables the authors to explore the disparity thoroughly through mediation analysis. They demonstrate that area-level SDOH, particularly measures of structural racism and practical obstacles, account for the majority of inequity in trial participation. Neighborhood racial and ethnic composition, a proxy for segregation, was considered the most substantial mediator and explained one-third of the inequities between Black, Latinx, and White patients. The authors point to site factors such as clinician bias and institutional racism and to sponsor factors such as their preference for partnering with well-resourced cancer care facilities, which tend not to serve minority populations. At the patient level, the authors ( 1) show that area-level vehicle ownership was an important mediator, highlighting a tangible opportunity to improve equity by providing transportation assistance. Limited proficiency in English was an important mediator of Latinx-White inequity and provides further evidence of the importance of providing reliable interpreter access and translated materials.

15 September 2023 in Internal Medicine Journal
Verified
Journal Article
Closed access
UNUdit Nindra
Udit Nindra
APAbhijit Pal
Abhijit Pal
VBVictoria Bray
Victoria Bray
PYPo Y. Yip
Po Y. Yip
ATAnnette Tognela
Annette Tognela
WCWei Chua
Wei Chua

6 September 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
APAbhijit Pal
Abhijit Pal
SSSarah Stapleton
Sarah Stapleton
CYChristina Yap
Christina Yap
JLJulia Lai-Kwon
Julia Lai-Kwon
RDRobert Daly
Robert Daly
JLJuanita Lopez
Juanita Lopez
Introduction Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures—this is reflected in the increasing length of participant information sheets (PIS). Informed consent for early phase clinical trials has been contentious due to the potential ethical issues associated with performing experimental research on a terminally ill population which has exhausted standard treatment options. Empirical studies have demonstrated significant gaps in patient understanding regarding the nature and intent of these trials. This study aims to test whether enhanced informed consent for patient education can improve patient scores on a validated questionnaire testing clinical trial comprehension. Methods and analysis This is a randomised controlled trial that will allocate patients who are eligible to participate in one of four investigator-initiated clinical trials at the Royal Marsden Drug Development Unit to either a standard arm or an experimental arm, stratified by age and educational level. The standard arm will involve the full length trial PIS, followed by electronic or paper administration of the Quality of Informed Consent Questionnaire Parts A and B (QuIC-A and QuIC-B). The experimental arm will involve the full length trial PIS, exposure to a two-page study aid and 10 online educational videos, followed by administration of the QuIC-A and QuIC-B. The primary endpoint will be the difference (using a one-sided two-sample t-test) in the QuIC-A score, which measures objective understanding, between the standard and experimental arm. Accrual target is at least 17 patients per arm to detect an 8 point difference (80% power, alpha 0.05). Ethics and dissemination Ethics approval was granted by the National Health Service Health Research Authority on 15 June 2020—IRAS Project ID 277065, Protocol Number CCR5165, REC Reference 20/EE/0155. Results will be disseminated via publication in a relevant journal. Trial registration number NCT04407676; Pre-results.

23 October 2025 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
JNJessie Nguyen
Jessie Nguyen
NBNicolò Matteo Luca Battisti
Nicolò Matteo Luca Battisti
DCDanielle Ní Chróinín
Danielle Ní Chróinín
MHMartin Hong
Martin Hong
UNUdit Nindra
Udit Nindra
APAbhijit Pal
Abhijit Pal